Gestational Diabetes Mellitus (GDM)
Glucose intolerance first identified during pregnancy — screen at 24-28 weeks; manage with diet, exercise, insulin.
Also known as: gestational diabetes, GDM, diabetes in pregnancy, pregnancy-related diabetes
Overview
Glucose intolerance with onset or first recognition during pregnancy that does not clearly meet criteria for overt diabetes. Distinguished from pregestational (type 1 or 2) diabetes diagnosed before pregnancy.
Epidemiology
Affects ~6-9% of US pregnancies; higher rates with rising obesity. Disproportionately affects Hispanic, Asian, Native American, and Black populations.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Gestational Diabetes Mellitus (GDM) outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- Obesity (BMI ≥30)
- Advanced maternal age (≥25, increased risk >35)
- Family history of diabetes (first-degree relative)
- Prior GDM, prior macrosomic infant (>4000 g), prior stillbirth
- PCOS
- Ethnicity (Hispanic, Asian, Native American, Black)
- Hypertension
- Glycosuria or HbA1c 5.7-6.4% before pregnancy
Pathophysiology
Placental hormones (human placental lactogen, growth hormone variant, cortisol, progesterone) progressively induce insulin resistance starting at ~20 weeks, requiring 2-3x baseline insulin secretion to maintain normoglycemia. Women with insufficient pancreatic β-cell reserve develop hyperglycemia. Maternal hyperglycemia → fetal hyperglycemia → fetal hyperinsulinemia → macrosomia, organomegaly, neonatal hypoglycemia.
Clinical presentation
Symptoms
- Usually asymptomatic — identified by screening
- Polyuria, polydipsia (uncommon)
- Macrosomia or polyhydramnios may be the presenting clue on ultrasound
Signs / physical exam
- Often normal exam
- Obesity, acanthosis nigricans
- Fundal height larger than dates
Differential diagnosis
- Undiagnosed pregestational type 2 diabetes — A1c ≥6.5% or fasting glucose ≥126 at first prenatal visit; warrants pregestational management
- Type 1 diabetes onset in pregnancy — Rare; ketoacidosis, severe hyperglycemia, often weight loss
- MODY — Family history pattern; genetic testing
- Stress hyperglycemia — Transient, related to acute illness
Diagnostic workup
Labs
- Early screening at first prenatal visit for high-risk women (BMI ≥30, prior GDM, A1c ≥5.7%, etc.) — A1c, fasting glucose, or 1-h GCT
- Universal screening at 24-28 weeks gestation
- Two-step approach (most common in US): 50 g 1-hour glucose challenge test (non-fasting) → if ≥130-140 mg/dL (institutional cutoff), proceed to 3-hour 100 g OGTT
- 3-hour OGTT diagnostic: ≥2 abnormal values (fasting ≥95, 1-h ≥180, 2-h ≥155, 3-h ≥140 mg/dL — Carpenter-Coustan criteria)
- One-step IADPSG/ADA alternative: 75 g 2-hour OGTT, abnormal if fasting ≥92, 1-h ≥180, or 2-h ≥153
Imaging
- Ultrasound for fetal growth at 28-32 weeks and again at 36 weeks; assess for macrosomia, polyhydramnios
- Antepartum testing (NST, BPP) starting 32-36 weeks in patients on medications or with poor glycemic control
Diagnostic algorithm
| Test | Timing | Cutoff | Interpretation |
|---|---|---|---|
| 50 g 1-h GCT (screen) | 24-28 weeks (universal) | ≥130-140 mg/dL | Abnormal → proceed to OGTT |
| 3-h 100 g OGTT | After abnormal GCT | Fasting ≥95, 1h ≥180, 2h ≥155, 3h ≥140 | ≥2 abnormal = GDM (Carpenter-Coustan) |
| 2-h 75 g OGTT (1-step) | 24-28 weeks | Fasting ≥92, 1h ≥180, 2h ≥153 | ≥1 abnormal = GDM (IADPSG) |
| Postpartum 75 g 2-h OGTT | 4-12 weeks postpartum | Fasting ≥126 or 2h ≥200 | Diagnose persistent T2DM |
Treatment
First-line
- Medical nutrition therapy — referral to registered dietitian; carbohydrate-controlled diet (~40% carbs, 20% protein, 40% fat), 3 meals + 2-3 snacks
- Exercise — 30 min moderate activity most days
- Self-monitoring of blood glucose 4 times daily: fasting + 1- or 2-hour postprandial
- Glycemic targets: fasting <95 mg/dL, 1-h postprandial <140, 2-h postprandial <120
Pharmacologic therapy (if MNT fails)
- Insulin — first-line pharmacotherapy per ACOG; does not cross placenta
- • Basal: NPH or detemir at bedtime ± morning
- • Bolus: regular insulin, aspart, or lispro before meals
- • Start ~0.7-1.0 U/kg/day total (gestational age dependent), split per pattern
- Metformin — alternative; crosses placenta; reasonable for women who decline insulin
- Glyburide — historically used but has fallen out of favor due to higher rates of macrosomia and neonatal hypoglycemia
Intrapartum
- Monitor glucose every 1-2 hours; target 70-110 mg/dL
- Insulin drip if hyperglycemic
- Avoid prolonged fasting; D5 in fluids if needed
- Continuous fetal monitoring
- Consider scheduled C-section if estimated fetal weight ≥4500 g (per ACOG)
Postpartum
- Discontinue insulin/oral agents after delivery
- Encourage breastfeeding
- 75 g 2-h OGTT at 4-12 weeks postpartum to screen for persistent type 2 diabetes
- Lifelong diabetes screening every 1-3 years (50% lifetime T2DM risk)
- Counsel about future pregnancy planning
Complications
- Maternal: preeclampsia (2-4x risk), polyhydramnios, cesarean delivery, type 2 diabetes after pregnancy (~50% within 10 years), recurrent GDM
- Fetal: macrosomia (>4000 g), shoulder dystocia, birth trauma (brachial plexus injury, fracture), stillbirth (poor control)
- Neonatal: hypoglycemia, hyperbilirubinemia, polycythemia, respiratory distress syndrome (delayed surfactant), hypocalcemia, cardiomyopathy
- Long-term offspring: childhood obesity, metabolic syndrome, type 2 diabetes
PANCE pearls
- Universal screening at 24-28 weeks gestation is recommended by ACOG; high-risk women should be screened at the first prenatal visit.
- Insulin is first-line pharmacologic therapy for GDM per ACOG; metformin is an alternative for women who decline insulin.
- Glyburide is associated with worse outcomes (macrosomia, neonatal hypoglycemia) than insulin or metformin; ACOG no longer recommends it as first-line.
- 75 g 2-hour OGTT at 4-12 weeks postpartum identifies persistent type 2 diabetes; lifetime follow-up screening is essential.
- Macrosomia warrants discussion of scheduled cesarean at EFW ≥4500 g (or ≥4000 g in diabetic pregnancies per some sources) to reduce shoulder dystocia.
- Diabetic ketoacidosis can occur at lower glucose levels in pregnancy (euglycemic DKA) — maintain high suspicion in symptomatic patients.
References
- ACOG PB 190 — ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
- ADA 2024 — ADA Standards of Care: Management of Diabetes in Pregnancy (Diabetes Care 2024)
- USPSTF 2021 — Screening for Gestational Diabetes: USPSTF Recommendation Statement (JAMA 2021)
- HAPO Study — Hyperglycemia and Adverse Pregnancy Outcomes (HAPO Study Cooperative Research Group, NEJM 2008)
Practice Reproductive questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.